Market Announcement
Mindsight AI Announces Launch of Temigis - New Zealand to Accelerate Life Sciences Intelligence
SYDNEY, AUSTRALIA — Mindsight AI today announced the launch of Temigis - New Zealand, the inaugural release of its AI-first intelligence platform designed to redefine how commercial, regulatory, and strategic leaders synthesise complex life sciences data into actionable outcomes.
Developed by experienced software engineers and life sciences data experts at Mindsight AI, Temigis bridges the gap between fragmented raw data and strategic decision-making. By unifying sources like Medsafe, PHARMAC and NZMT dataset into a single, AI-optimised database and adding life-sciences reasoning capabilities, Temigis will ultimately deliver consultant-grade analysis in seconds rather than weeks.
Addressing an Urgent Industry Need
Whilst preparing for the official launch of the broader ANZ platform, recent outages to the Medsafe Product/Application Search database, the primary public tool for searching medicines approvals in New Zealand, created a significant gap for life sciences professionals. In response, Mindsight AI accelerated the release of its New Zealand tools, making the Temigis - New Zealand 'Lite' tier available at no cost for a limited time to support the industry.
The platform provides seamless access to verified regulatory and market data, featuring purpose-built tools for Sponsor, Product, Active Ingredient, and ATC code searches, as well as tracking new market Applications, Approvals, and Withdrawals.
The Temigis interface: Clean, intuitive, and built for complex data synthesis.
Eliminating the Guesswork of Mainstream AI
Unlike general AI tools such as ChatGPT or Gemini, which are often unsuitable for high-stakes regulatory environments, every Temigis response is deterministic and strictly grounded in up-to-date, standardised data. It acts as a specialist consultant that understands the clinical, commercial, and regulatory nuances of the market on demand.
"The life sciences sector is drowning in data but starving for insight," said Leighton Howard, CEO of Mindsight AI. "For too long, leaders have been forced to spend valuable time manually cross-referencing disparate and inconsistent sources. Temigis is our response — a platform that strictly grounds its answers in verified data to remove the guesswork, delivering insights at the pace the industry demands."
Over the coming weeks, New Zealand pricing and reimbursement capabilities will be further enhanced, followed by a major expansion to include Australian (TGA and PBS) data.
Availability
For a limited time, the Temigis - New Zealand 'Lite' tier is available at no cost. Users can instantly generate comprehensive market overviews and access limited monthly analytical tokens, with optional upgrades to higher subscription tiers. Register now to lock in free access at temigis.com.
About Mindsight AI
Mindsight AI is a technology company dedicated to building advanced, AI-first intelligence solutions for the life sciences sector. By unifying fragmented regulatory, medical, and commercial data, Mindsight AI empowers industry leaders to accelerate research, mitigate risk, and drive strategic decision-making.